International Isotopes Inc. $(INIS)$ has announced its financial results for the second quarter and the first six months ending June 30, 2025. The company reported a 15.3% increase in revenue from product sales for the second quarter of 2025, reaching $3.7 million, compared to the same period in 2024. For the first half of 2025, product sales rose by 13.5% to $6.9 million. The net loss for the second quarter of 2025 improved by 31.1% to $160,785 from a loss of $233,445 in the same period last year. Over the first six months of 2025, the net loss improved by 29.4% to $273,479 from $387,496 in the corresponding period of the previous year. The company's non-GAAP EBITDA for the second quarter increased to $1,199, a rise of $85,202, while the six-month figure improved by 157%, reaching $51,569. These financial improvements were largely driven by the robust performance in sales of Nuclear Medicine Standards products and Cobalt products.